News
Wed, 03 Nov 2021 05:35:00 -0400
Wed, 03 Nov 2021 05:35:00 -0400
3 November 2021
|
PROFIT AND LOSS |
9M 2021 |
9M 2020 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
16,487 |
14,274 |
8% |
13% |
|
Operating profit |
7,242 |
6,466 |
5% |
12% |
|
|
|
|
|
|
|
Net profit |
5,931 |
4,941 |
12% |
N/A |
|
Diluted earnings per share (in USD) |
2.57 |
2.11 |
14% |
N/A |
* CER: Constant exchange rates (average 2020).
**For convenience, Danish kroner for 9M 2021 has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.21513 and the period-end exchange rate of USD 1.0 = DKK 6.42197
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first nine months of 2021 which has enabled us to raise our outlook for the full year. The growth is driven by all geographical areas and by all therapy areas, in particular by accelerated growth of our portfolio of GLP-1 treatments for diabetes and obesity. In the US, the initial demand for Wegovy™ has significantly exceeded our expectations, underscoring the high unmet need for people living with obesity. With the initiation of two phase 3 programmes in the third quarter, we continue to expand our late-stage clinical pipeline."
On 3 November 2021 at 13.00 CET, corresponding to 08.00 AM EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.